## **Special Issue**

# Affective Disorders Psychopharmacology

## Message from the Guest Editor

This Special Issue, 'Affective Disorders
Psychopharmacology', welcomes articles addressing
current pharmacological approaches to treating
affective disorders, and research work that explores
limitations of existing strategies and/or offer
perspectives related to novel pharmacological
treatments.

The issue also welcomes articles reporting new strategies for detecting responsiveness to treatments and refractoriness in relation to the use of pharmacology in affective disorders by utilising a range of technologies including those that explore brain structure and function, putative peripheral markers of affective disorders, and genetic makeup/variation across the spectrum of affective disorders. We also encourage the submission of articles that compare pharmacological strategies with alternative treatment methods, particularly in relation to important topics such as treatment response, aetiological mechanisms, patients' preferences, etc.

### **Guest Editor**

Dr. Danilo Arnone

- Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada
   Mental Health Department, The Ottawa Hospital, Ottawa, ON, Canada
- King's College London, Institute of Psychiatry, Psychology and Neuroscience, Psychological Medicine, Centre for Affective Disorders, London, UK

## Deadline for manuscript submissions

15 October 2025



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/200453

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

